Organogenesis (ORGO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ORGO Stock Forecast

Organogenesis stock forecast is as follows: an average price target of $5.00 (represents a 60.77% upside from ORGO’s last price of $3.11) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ORGO Price Target

The average price target for Organogenesis (ORGO) is $5.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 60.77% upside from ORGO's last price of $3.11.

ORGO Analyst Ratings

Buy

According to 3 Wall Street analysts, Organogenesis's rating consensus is 'Buy'. The analyst rating breakdown for ORGO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Organogenesis Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 28, 2024	Brooks O'Neil	Lake Street	$5.00	$2.64	89.39%	60.77%

The latest Organogenesis stock forecast, released on Jun 28, 2024 by Brooks O'Neil from Lake Street, set a price target of $5.00, which represents a 89.39% increase from the stock price at the time of the forecast ($2.64), and a 60.77% increase from ORGO last price ($3.11).

Organogenesis Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$5.00
Last Closing Price	$3.11	$3.11	$3.11
Upside/Downside	-100.00%	-100.00%	60.77%

In the current month, the average price target of Organogenesis stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Organogenesis's last price of $3.11. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jun 28, 2024	Lake Street		Buy	Initialise
Dec 27, 2023	BTIG	Buy	Buy	Hold
May 24, 2023	WestPark Capital		Hold	Initialise
May 24, 2023	BTIG		Buy	Upgrade

Organogenesis's last stock rating was published by Lake Street on Jun 28, 2024. The company Initialise its ORGO rating from "null" to "Buy".

Organogenesis Financial Forecast

Organogenesis Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	-	-	-	-	-	-	-	-	-	$108.53M	$117.32M	$107.64M	$115.52M	$116.86M	$121.40M	$98.12M	$128.56M	$113.75M	$123.20M	$102.55M	$106.81M	$100.80M	$68.96M	$61.73M	$74.64M	$64.27M	$64.95M	$57.12M
Avg Forecast	$129.59M	$123.86M	$134.88M	$114.65M	$109.61M	$108.83M	$121.30M	$101.06M	$109.06M	$111.43M	$115.09M	$95.52M	$122.40M	$120.85M	$120.91M	$95.95M	$124.71M	$112.24M	$105.95M	$86.09M	$105.25M	$71.95M	$58.82M	$60.90M	$70.40M	$62.97M	$60.35M	$52.60M
High Forecast	$131.46M	$125.66M	$136.83M	$116.31M	$111.20M	$109.16M	$123.06M	$102.53M	$110.64M	$111.43M	$116.76M	$96.90M	$124.17M	$120.85M	$120.91M	$95.95M	$124.71M	$112.24M	$105.95M	$86.09M	$105.25M	$71.95M	$58.82M	$60.90M	$70.40M	$62.97M	$60.35M	$52.60M
Low Forecast	$127.87M	$122.22M	$133.09M	$113.13M	$108.16M	$108.51M	$119.69M	$99.72M	$107.61M	$111.43M	$113.56M	$94.25M	$120.78M	$120.85M	$120.91M	$95.95M	$124.71M	$112.24M	$105.95M	$86.09M	$105.25M	$71.95M	$58.82M	$60.90M	$70.40M	$62.97M	$60.35M	$52.60M
# Analysts	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	0.97%	1.02%	1.13%	0.94%	0.97%	1.00%	1.02%	1.03%	1.01%	1.16%	1.19%	1.01%	1.40%	1.17%	1.01%	1.06%	1.02%	1.08%	1.09%

Organogenesis's average Quarter revenue forecast for Dec 23 based on 1 analysts is $109.06M, with a low forecast of $107.61M, and a high forecast of $110.64M. ORGO's average Quarter revenue forecast represents a 0.48% increase compared to the company's last Quarter revenue of $108.53M (Sep 23).

Organogenesis EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	$8.05M	$13.23M	$1.89M	$8.72M	$6.29M	$16.46M	$5.28M	$25.27M	$19.09M	$27.34M	$15.99M	$23.98M	$25.82M	$-520.00K	$-12.05M	$600.00K	$-5.95M	$-5.08M	$-11.43M
Avg Forecast	$9.97M	$9.53M	$10.38M	$8.82M	$8.43M	$8.37M	$9.33M	$7.78M	$8.39M	$8.57M	$8.85M	$7.35M	$9.42M	$9.65M	$9.66M	$9.45M	$9.96M	$8.96M	$8.46M	$79.18M	$8.41M	$5.75M	$4.70M	$-9.27M	$5.62M	$5.03M	$4.82M	$-5.72M
High Forecast	$10.11M	$9.67M	$10.53M	$8.95M	$8.56M	$8.40M	$9.47M	$7.89M	$8.51M	$8.57M	$8.98M	$7.46M	$9.55M	$9.65M	$9.66M	$11.34M	$9.96M	$8.96M	$8.46M	$95.01M	$8.41M	$5.75M	$4.70M	$-7.41M	$5.62M	$5.03M	$4.82M	$-4.57M
Low Forecast	$9.84M	$9.40M	$10.24M	$8.70M	$8.32M	$8.35M	$9.21M	$7.67M	$8.28M	$8.57M	$8.74M	$7.25M	$9.29M	$9.65M	$9.66M	$7.56M	$9.96M	$8.96M	$8.46M	$63.34M	$8.41M	$5.75M	$4.70M	$-11.12M	$5.62M	$5.03M	$4.82M	$-6.86M
Surprise %	-	-	-	-	-	-	-	-	-	0.94%	1.49%	0.26%	0.93%	0.65%	1.70%	0.56%	2.54%	2.13%	3.23%	0.20%	2.85%	4.49%	-0.11%	1.30%	0.11%	-1.18%	-1.05%	2.00%

1 analysts predict ORGO's average Quarter EBITDA for Dec 23 to be $8.39M, with a high of $8.51M and a low of $8.28M. This is 4.23% upper than Organogenesis's previous annual EBITDA (Sep 23) of $8.05M.

Organogenesis Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	$12.11M	$5.32M	$-2.97M	$7.49M	$215.00K	$8.74M	$87.00K	$51.70M	$12.58M	$20.69M	$9.94M	$18.49M	$20.93M	$-5.17M	$-16.31M	$-4.40M	$-10.74M	$-9.65M	$-15.67M
Avg Forecast	$5.38M	$5.68M	$6.55M	$2.93M	$-1.52M	$-2.68M	$669.63K	$-3.12M	$1.12M	$1.49M	$4.14M	$-2.65M	$6.70M	$7.87M	$10.73M	$155.54K	$10.98M	$8.28M	$7.62M	$49.22M	$16.31M	$-10.61M	$-29.96M	$-12.55M	$-12.26M	$-16.79M	$-17.23M	$-7.83M
High Forecast	$5.49M	$5.79M	$6.67M	$2.99M	$-1.50M	$-2.63M	$682.24K	$-3.07M	$1.14M	$1.50M	$4.22M	$-2.61M	$6.82M	$7.87M	$10.73M	$186.65K	$10.98M	$8.28M	$7.62M	$59.06M	$16.31M	$-10.61M	$-29.96M	$-10.04M	$-12.26M	$-16.79M	$-17.23M	$-6.27M
Low Forecast	$5.29M	$5.58M	$6.44M	$2.88M	$-1.55M	$-2.73M	$658.08K	$-3.18M	$1.10M	$1.48M	$4.07M	$-2.70M	$6.58M	$7.87M	$10.73M	$124.43K	$10.98M	$8.28M	$7.62M	$39.37M	$16.31M	$-10.61M	$-29.96M	$-15.06M	$-12.26M	$-16.79M	$-17.23M	$-9.40M
Surprise %	-	-	-	-	-	-	-	-	-	8.11%	1.28%	1.12%	1.12%	0.03%	0.82%	0.56%	4.71%	1.52%	2.71%	0.20%	1.13%	-1.97%	0.17%	1.30%	0.36%	0.64%	0.56%	2.00%

Organogenesis's average Quarter net income forecast for Dec 23 is $1.12M, with a range of $1.10M to $1.14M. ORGO's average Quarter net income forecast represents a -90.74% decrease compared to the company's last Quarter net income of $12.11M (Sep 23).

Organogenesis SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	$64.22M	$70.32M	$73.83M	$68.29M	$79.33M	$72.61M	$63.58M	$67.25M	$62.37M	$62.35M	$58.23M	$53.22M	$51.15M	$46.50M	$52.61M	$52.37M	$49.48M	$48.96M	$48.89M
Avg Forecast	$81.73M	$78.12M	$85.07M	$72.31M	$69.13M	$68.64M	$76.50M	$63.74M	$68.78M	$70.28M	$72.58M	$60.24M	$77.20M	$74.70M	$74.74M	$59.30M	$77.09M	$69.37M	$65.49M	$53.21M	$65.06M	$44.47M	$36.36M	$40.47M	$43.51M	$38.92M	$37.30M	$24.45M
High Forecast	$82.91M	$79.25M	$86.30M	$73.36M	$70.13M	$68.84M	$77.61M	$64.66M	$69.78M	$70.28M	$73.64M	$61.11M	$78.31M	$74.70M	$74.74M	$59.30M	$77.09M	$69.37M	$65.49M	$53.21M	$65.06M	$44.47M	$36.36M	$48.57M	$43.51M	$38.92M	$37.30M	$29.34M
Low Forecast	$80.64M	$77.08M	$83.94M	$71.35M	$68.21M	$68.44M	$75.49M	$62.89M	$67.87M	$70.28M	$71.62M	$59.44M	$76.17M	$74.70M	$74.74M	$59.30M	$77.09M	$69.37M	$65.49M	$53.21M	$65.06M	$44.47M	$36.36M	$32.38M	$43.51M	$38.92M	$37.30M	$19.56M
Surprise %	-	-	-	-	-	-	-	-	-	0.91%	0.97%	1.23%	0.88%	1.06%	0.97%	1.07%	0.87%	0.90%	0.95%	1.09%	0.82%	1.15%	1.28%	1.30%	1.20%	1.27%	1.31%	2.00%

Organogenesis's average Quarter SG&A projection for Dec 23 is $68.78M, based on 1 Wall Street analysts, with a range of $67.87M to $69.78M. The forecast indicates a 7.10% rise compared to ORGO last annual SG&A of $64.22M (Sep 23).

Organogenesis EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	$0.09	$0.04	$-0.02	$0.06	-	$0.07	-	$0.40	$0.10	$0.16	$0.08	$0.16	$0.20	$-0.05	$-0.16	$-0.04	$-0.12	$-0.11	$-0.17
Avg Forecast	$0.04	$0.04	$0.05	$0.02	$-0.01	$-0.02	$0.01	$-0.02	$0.01	$0.01	$0.03	$-0.02	$0.05	$0.06	$0.08	$0.05	$0.08	$0.06	$0.06	$-0.02	$0.12	$-0.08	$-0.23	$-0.13	$-0.09	$-0.13	$-0.13	$-0.11
High Forecast	$0.04	$0.04	$0.05	$0.02	$-0.01	$-0.02	$0.01	$-0.02	$0.01	$0.01	$0.03	$-0.02	$0.05	$0.06	$0.08	$0.05	$0.08	$0.06	$0.06	$-0.02	$0.12	$-0.08	$-0.23	$-0.13	$-0.09	$-0.13	$-0.13	$-0.11
Low Forecast	$0.04	$0.04	$0.05	$0.02	$-0.01	$-0.02	-	$-0.02	$0.01	$0.01	$0.03	$-0.02	$0.05	$0.06	$0.08	$0.05	$0.08	$0.06	$0.06	$-0.02	$0.12	$-0.08	$-0.23	$-0.13	$-0.09	$-0.13	$-0.13	$-0.11
Surprise %	-	-	-	-	-	-	-	-	-	8.27%	1.29%	1.14%	1.20%	0.03%	0.87%	0.01%	4.83%	1.60%	2.78%	-4.32%	1.30%	-2.50%	0.22%	1.20%	0.43%	0.95%	0.85%	1.59%

According to 1 Wall Street analysts, Organogenesis's projected average Quarter EPS for Dec 23 is $0.01, with a low estimate of $0.01 and a high estimate of $0.01. This represents a -90.93% decrease compared to ORGO previous annual EPS of $0.09 (Sep 23).

Organogenesis Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
DVAX	Dynavax	$12.90	$29.00	124.81%	Buy
ORGO	Organogenesis	$3.57	$5.00	40.06%	Buy
COLL	Collegium Pharmaceutical	$30.90	$42.33	36.99%	Buy
ALKS	Alkermes	$30.75	$37.50	21.95%	Hold
NBIX	Neurocrine Biosciences	$136.69	$156.14	14.23%	Buy
ITCI	Intra-Cellular Therapies	$86.96	$93.33	7.33%	Buy
LFCR	Lifecore Biomedical	$7.47	$6.50	-12.99%	Buy

ORGO Forecast FAQ

Is Organogenesis a good buy?

Yes, according to 3 Wall Street analysts, Organogenesis (ORGO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of ORGO's total ratings.

What is ORGO's price target?

Organogenesis (ORGO) average price target is $5 with a range of $5 to $5, implying a 60.77% from its last price of $3.11. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Organogenesis stock go up soon?

According to Wall Street analysts' prediction for ORGO stock, the company can go up by 60.77% (from the last price of $3.11 to the average price target of $5), up by 60.77% based on the highest stock price target, and up by 60.77% based on the lowest stock price target.

Can Organogenesis stock reach $5?

ORGO's average twelve months analyst stock price target of $5 does not support the claim that Organogenesis can reach $5 in the near future.

What are Organogenesis's analysts' financial forecasts?

Organogenesis's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $440.81M (high $445.94M, low $436.08M), average EBITDA is $33.92M (high $34.31M, low $33.55M), average net income is $-6.657M (high $-6.518M, low $-6.807M), average SG&A $278.01M (high $281.25M, low $275.03M), and average EPS is $-0.0497 (high $-0.0487, low $-0.0508). ORGO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $502.98M (high $510.26M, low $496.3M), average EBITDA is $38.7M (high $39.26M, low $38.19M), average net income is $20.54M (high $20.93M, low $20.19M), average SG&A $317.22M (high $321.81M, low $313.01M), and average EPS is $0.153 (high $0.156, low $0.151).

Did the ORGO's actual financial results beat the analysts' financial forecasts?

Based on Organogenesis's last annual report (Dec 2023), the company's revenue was $433.14M, beating the average analysts forecast of $431.09M by 0.48%. Apple's EBITDA was $12.52M, missing the average prediction of $33.17M by -62.24%. The company's net income was $15.84M, beating the average estimation of $4.1M by 286.28%. Apple's SG&A was $269.75M, missing the average forecast of $271.88M by -0.78%. Lastly, the company's EPS was $0.0001, missing the average prediction of $0.0306 by -99.67%. In terms of the last quarterly report (Sep 2023), Organogenesis's revenue was $108.53M, missing the average analysts' forecast of $111.43M by -2.60%. The company's EBITDA was $8.05M, missing the average prediction of $8.57M by -6.10%. Organogenesis's net income was $12.11M, beating the average estimation of $1.49M by 710.76%. The company's SG&A was $64.22M, missing the average forecast of $70.28M by -8.61%. Lastly, the company's EPS was $0.0922, beating the average prediction of $0.0112 by 726.91%